Neoadjuvant atirmociclib plus letrozole versus letrozole alone in HR+/HER2− breast cancer: Results from FourLight-2, a randomized phase 2 window of opportunity study.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Shom Goel, Isabel Blancas, Giacomo Allegrini, Jose Luis Alonso-Romero, Alvaro Rodriguez-Lescure, Sara Lopez-Tarruella Cobo, Aleksandra Grela-Wojewoda, Thomas Grinda, Cristian Villanueva, Samanta Sarti, Christian Kurzeder, Ilke Cikman, Muralidhar Beeram, Kuo-Ting Lee, Cynthia Basu, Sindy Kim, Feng Liu, Jin Yao, Michail Ignatiadis
Institutions: Peter MacCallum Cancer Centre, Instituto de Investigación Biosanitaria de Granada, Azienda USL Toscana Nord Ovest, Instituto Murciano de Investigación Biosanitaria, Hospital Universitario Virgen de la Arrixaca, Hospital General Universitario de Elche, Hospital General Universitario Gregorio Marañón, Institut Gustave Roussy, Clinique Clémentville, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, University Hospital of Basel, Gävle Hospital, South Texas Accelerated Research Therapeutics, National Cheng Kung University Hospital, Pfizer (United States), Institut Jules Bordet
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Pfizer
OpenAlex ID: W7162496862
Cites:
Cited by:
Related to: